Holoprosencephaly (HPE) is a common developmental defect caused by failure to define the midline of the forebrain and/or midface. HPE is associated with heterozygous mutations in Nodal and Sonic hedgehog (SHH) pathway components, but clinical presentation is highly variable, and many mutation carriers are unaffected. It is therefore thought that such mutations interact with more common modifiers, genetic and/or environmental, to produce severe patterning defects. Modifiers are difficult to identify, as their effects are context-dependent and occur within the complex genetic and environmental landscapes that characterize human populations. This has made a full understanding of HPE etiology challenging. We discuss here the use of mice, a genetically tractable model sensitive to teratogens, as a system to address this challenge. Mice carrying mutations in human HPE genes often display wide variations in phenotypic penetrance and expressivity when placed on different genetic backgrounds, demonstrating the existence of silent HPE modifier genes. Studies with mouse lines carrying SHH pathway mutations on appropriate genetic backgrounds have led to identification of both genetic and environmental modifiers that synergize with the mutations to produce a spectrum of HPE phenotypes. These models favor a scenario in which multiple modifying influences-both genetic and environmental, sensitizing and protective-interact with bona fide HPE mutations to grade phenotypic outcomes. Despite the complex interplay of HPE risk factors, mouse models have helped establish some clear concepts in HPE etiology. A combination of mouse and human cohort studies should improve our understanding of this fascinating and medically important issue.
| I N TR ODU C TI ON
Holoprosencephaly (HPE; OMIM 236100) is a developmental defect in midline patterning of the forebrain and midface (Muenke & Beachy, 2001) . It is remarkably common, occurring about once in 250 conceptions, but with 97% succumbing in utero (Leoncini et al., 2008; Shiota & Yamada, 2010) . HPE encompasses a spectrum of anomalies. A phenotypic continuum of defects is broadly classified into three categories based on the degree of midline cleavage of the forebrain (Muenke et al., 2001) . Alobar HPE, the most severe form, is characterized by complete failure to partition the forebrain into left and right hemispheres; semilobar and lobar HPE are progressively less severe subtypes. The spectrum of craniofacial anomalies ranges from cyclopia in the most severe cases to single nostril, midface hypoplasia with midline cleft lip and/or palate, and single maxillary central incisor in progressively less affected individuals. The least severe facial midline anomalies may occur in the absence of brain malformations and are referred to as microforms of HPE.
The etiology of HPE is complex and heterogeneous (Krauss, 2007; Lipinski, Godin, O'leary-Moore, Parnell, & Sulik, 2010; . It may be caused by large cytogenetic aberrations and/ or occur as a feature of an identifiable syndrome. Isolated (nonchromosomal, nonsyndromic) HPE occurs in both familial and sporadic forms, and is the focus of this review. Heterozygous, loss-of-function mutations in components and regulators of the Nodal and Hedgehog (Hh) signaling pathways are associated with HPE . However, in only a minority of isolated HPE cases have mutations been identified . Clinical presentation is extremely variable, with the full phenotypic spectrum seen in both sporadic and familial cases (Muenke et al., 2001; Solomon et al., 2010) .
Furthermore, incomplete penetrance and variable expressivity are observed in pedigrees with heterozygous null mutations in SHH and SIX3 (Lacbawan et al., 2009; Solomon et al., 2012; Stokes et al., 2018) . Additionally, mutations in these genes identified in sporadic cases are most often inherited from a parent with little or no clinical manifestation (Lacbawan et al., 2009; Solomon et al., 2012) . These observations are generally interpreted to indicate that most HPE-associated mutations are insufficient to cause severe, or possibly any, defects in forebrain patterning. Statistical analyses of this scenario led to a multifactorial, "autosomal dominant with modifier" model, in which the phenotypic outcome associated with a heterozygous mutation is influenced by more common genetic variants and/or environmental exposures (Roessler, V elez, Zhou, & Muenke, 2012) .
Nongenetic (environmental) risk factors are widely thought to be important in HPE etiology. In utero exposure to specific teratogens, including Hh pathway inhibitors, is sufficient to induce HPE in agricultural and experimental animals (Chen, 2016; .
However, epidemiological studies on HPE have been incomplete and inconclusive (Croen, Shaw, & Lammer, 2000; Johnson & Rasmussen, 2010; Miller et al., 2010; Stashinko et al., 2004) . It is suspected that many structural birth defects are caused by a complex combination of genetic and environmental factors that interact to perturb morphogenetic processes (Krauss & Hong, 2016) . The "autosomal dominant with modifier" model of HPE is wholly consistent with this likelihood, further complicating identification of environmental risk factors. Even though only a fraction of HPE cases currently have an identifiable genetic defect, it can be envisaged that future whole genome sequencing efforts will lead to a reasonably complete catalog of the genes that suffer true driver mutations in HPE. In contrast, modifiers, both genetic and environmental, are difficult to identify as their effects are contextdependent and occur within the complex genetic and environmental landscapes that characterize human populations.
One way to gain insight into these problems in studying HPE etiology is via animal models, particularly mice (Krauss, 2007; Schachter & Krauss, 2008) . Several properties of laboratory mice, including genetic tractability, and conserved signaling and developmental processes, make them the current model of choice. In this review, we discuss the strengths and weaknesses of using mice to address and illuminate questions of HPE etiology.
| R A TI ON AL E FOR TH E M OU SE A S A M OD EL OR GA N ISM FOR STU D YI N G T HE C OM PL EX ET IOL OGY OF H PE
Development of the midline of the forebrain and midface is initiated by signals from the prechordal mesendoderm (PCM) (Kiecker & Niehrs, 2001; Muenke & Beachy, 2000; Rubenstein & Beachy, 1998 ). The PCM is specified from the anterior primitive streak in response to signaling by the Nodal pathway (Schier, 2009; Shen, 2007) . Sonic Hh (Shh) produced by the PCM then initiates a developmental sequence which progressively patterns the rostroventral midline. Shh is expressed in a temporal cascade, first in the PCM, then in the developing ventral midline of the diencephalon and telencephalon, and induces ventral midline cell fates throughout this process (Aoto et al., 2009; Cordero et al., 2004; Geng et al., 2008; Marcucio, Cordero, Hu, & Helms, 2005; McMahon, Ingham, & Tabin, 2003; Rubenstein & Beachy, 1998) . As embryogenesis proceeds, Shh produced by the forebrain induces Shh expression in the ectoderm of the frontonasal and maxillary processes of the developing face. Shh from these latter structures patterns neural crest-derived facial primordia to produce specific cartilaginous structures and bones of the craniofacial midline (Helms, Cordero, & Tapadia, 2005; Hu & Helms, 1999; Hu & Marcucio, 2009; Marcucio, Young, Hu, & Hallgrimsson, 2011; Marcucio et al., 2005) .
Nodal and Shh activate evolutionarily conserved signal transduction pathways. Nodal is a TGFb superfamily member that signals via a receptor complex comprising TGFb type I and type II receptors (Alk4 and Acvr2A/B) and a glycophosphatidylinositol (GPI)-linked coreceptor (Cripto/TDGF1) ( Figure 1a ) (Schier, 2009; Shen, 2007) Heterozygous mutations in a limited number of genes are implicated as driver events in isolated and/or microform human HPE.
Almost all these genes are components or regulators (direct or indirect) of the Nodal or Shh signaling pathways. Those associated with Nodal include: NODAL, TDGF1 (human ortholog of mouse Cripto), FOXH1, and ZIC2; those associated with SHH include: SHH, DISP1, PTCH1, CDON, GAS1, and SIX3 Barratt & Arkell, 2018; PinedaAlvarez et al., 2012; Ribeiro, Quiezi, Nascimento, Bertolacini, & Richieri-Costa, 2010; . Mutation of GLI2, a key player in SHH signaling, results more commonly in pituitary deficits and mild facial anomalies, and only rarely in HPE (Bear et al., 2014; Roessler et al., 2003 ). TGIF1 appears to regulate both Nodal and SHH pathways by at least partially independent mechanisms (Taniguchi et al., 2016) . Mutations in FGF signaling pathway components are also found in human HPE (Arauz et al., 2010; Dubourg et al., 2016) .
When tested in functional assays, virtually all such mutations confer a loss of function, indicating patients are haploinsufficient, or partially compromised (Geng & Oliver, 2009; (we note that PTCH1 is a negative regulator of SHH signaling, so HPE-associated mutations presumably have a gain of function, but this has not been studied). Importantly, mutation of each of these genes (excluding Ptch1) produces HPE in mice, although the genetics are not identical between humans and mice. Most importantly, heterozygous mutations do not cause HPE in mice. We are aware of one exception:
Six3
1/-mice on a C57BL/6 genetic background had HPE with low penetrance (Geng et al., 2008) . We also note that while heterozygous mutants of Nodal, Cripto, and FoxH1 are without obvious phenotype, homozygous mutants do not have HPE either, because they fail to complete gastrulation and die in utero at a very early stage of development. However, strong hypomorphs in the Nodal pathway display a range of phenotypes that includes HPE (Chu et al., 2005; Lowe, Yamada, & Kuehn, 2001; Nomura & Li, 1998; Song et al., 1999) . Therefore, HPE is generally an autosomal recessive phenotype in mice, whereas it is autosomal dominant with partial penetrance and variable expressivity in human pedigrees. The phenomenon that mice require homozygous mutations to produce phenotypes associated with heterozygous mutations in humans is not restricted to HPE (Krauss, 2008) . (the range of modifiers experienced by gestating laboratory mice is likely to be much less complex); and (c) homozygous mutation of HPE genes in humans is likely to result in early embryonic lethality and pregnancy loss. Nevertheless, the fact that mutations in the same sets of genes in mice and humans are associated with HPE argues powerfully that the signaling and embryonic processes underlying development of the rostroventral midline are very similar between these species. This is hardly surprising, but serves as a critical basis for using mice to model the complex, multifactorial etiology of human HPE.
| G EN ET I C I N TER A CTI ON S I N HU M A N A N D M OU SE M OD EL S OF H P E
In seeking potential explanations for the insufficiency of heterozygous mutations to result in severe HPE anomalies, one early proposal was a need for heterozygosity of two different HPE genes; that is, digenic mutation (Ming & Muenke, 2002) . However, double heterozygosity for known, bona fide HPE genes occurs infrequently in human HPE (Lacbawan et al., 2009; Roessler et al., 2012; Solomon et al., 2012) .
Furthermore, the likelihood of developing HPE upon inheritance of a heterozygous mutation is too high to be explained by a second de novo mutation and therefore inconsistent with the analyses that led to the "autosomal dominant with modifier" model. (Geng et al., 2008; Heyne et al., 2016) . Therefore, there is selectivity to which genes in the Shh network produce HPE as an outcome of double haploinsufficiency. Given that weak alleles of HPE genes might function as modifiers (see below), such studies could help illuminate which gene variant combinations might contribute to HPE, when studying these more subtly affected alleles.
An alternative possibility to digenic mutation is that loss-offunction driver mutations interact with modifier alleles, some of which may be relatively common in human populations. It seems likely that two types of HPE modifier gene exist. First, weak hypomorphic alleles of bona fide HPE genes may be present in the general population, but the degree of function retained is insufficient to act as a driver mutation for HPE. However, such alleles may act as modifiers of strong lossof-function mutations in different HPE genes. Many variations of HPE genes are present in the human population but they will need to be assessed functionally to know whether they fit into this category (or act similarly to alleles considered as wild type Some of these loci may modify the phenotypic manifestation of unlinked mutant genes. For example, Cdon -/-mice on a C57BL/6 genetic background had semilobar HPE and a single nostril with high penetrance, whereas these mice on a 129S6 background showed only HPE microforms with low penetrance (Cole & Krauss, 2003; Zhang, Kang, Cole, Yi, & Krauss, 2006) (Figure 2 ). Therefore, Cdon -/-mice recapitulated a major portion of the HPE phenotypic spectrum simply by altering the strain background modifier genes. These results demonstrated that modifier genes are sufficient to grade HPE penetrance and expressivity in mice. In addition, they strongly suggest that such modifiers are one likely explanation for the phenotypic variability that characterizes human HPE. The C57BL/6 strain is a sensitized background for HPE induced by several mutations, including Cdon, Six3, Gli2, and Tsg (Tsg is a regulator of bone morphogenetic protein signaling not found to be mutated in human HPE) (Geng et al., 2008; Heyne et al., 2016; Petryk et al., 2004; Zhang et al., 2006) . The modifier loci in C57BL/6 mice that confer sensitivity to HPE by these various mutations are not known, and they may not be identical in each case.
The relatively HPE-resistant 129S6 Cdon -/-mice offer an opportunity to identify candidate modifiers, both genetic and environmental, silent or otherwise. These mice have a largely subthreshold defect in Shh signaling that is subject to modification, as evidenced by the increased severity of the HPE phenotype associated with a transfer to the C57BL/6 background (Cole & Krauss, 2003; Zhang et al., 2006) .
Cdon, Boc, and Gas1 are cell surface proteins that promote Hh pathway activity as ligand-binding coreceptors with Ptch1 (Allen, Tenzen, & McMahon, 2007; Allen et al., 2011; Izzi et al., 2011; Okada et al., 2006; Tenzen et al., 2006; Zhang, Hong, Bae, Kang, & Krauss, 2011; Zhang et al., 2006) . Cdon and Boc are closely related Ig superfamily members, whereas Gas1 is a GPI-anchored protein unrelated to Cdon and Boc. Analysis of mice with targeted mutations in Cdon, Boc, and Gas1, singly or in combination, indicated that these three factors have overlapping and partially compensatory functions in regulating Shh signaling (Allen et al., 2007 (Allen et al., , 2011 Izzi et al., 2011; Tenzen et al., 2006; Zhang et al., 2006 Zhang et al., , 2011 . Mice lacking any two coreceptors have stronger phenotypes than mice lacking any single one, and mice lacking all three have a nearly complete loss of Hh pathway activity.
Heterozygous mutations of CDON and GAS1 have been identified in human HPE patients Pineda-Alvarez et al., 2012; Ribeiro et al., 2010) . Consistent with this, Cdon -/-and Gas1 -/-mice display a range of HPE phenotypes (Cole & Krauss, 2003; Seppala et al., 2007; Zhang et al., 2006) . In contrast, Boc -/-mice do not have HPE on any genetic background, and they are viable and fertile (Okada et al., 2006; Zhang et al., 2011) . However, genetic removal of Boc from Cdon -/-mice worsens their HPE phenotype, and this is seen with mice on both 129S6 or C57BL/6 backgrounds (Zhang et al., 2011) (Figure 2 ;Boc -/-mice (Zhang et al., 2011) . Removal of Boc from Gas1 -/-mice also exacerbates the latter's HPE, although in this case both copies of Boc must be lost for the effect to be manifest (Seppala, Xavier, Fan, & Cobourne, 2014) .
From these results, it was concluded that Boc is a silent HPE modifier gene in mice. This naturally raised the possibility that BOC might also be a silent modifier in human HPE. To begin to assess this possibility, BOC was sequenced for 360 HPE patients and a similar number of unrelated individuals as controls (Hong et al., 2017) . Several variants were identified in the regions of BOC that: (a) physically interact with SHH or PTCH1; and (b) were equivalent to regions of CDON subject to loss-of-function mutations in HPE patients. These BOC variants were tested by in vitro functional assays, and two (R533L and P828R)
were associated with a loss of function. Importantly, some patients with these variants also had pathogenic mutations in known HPE genes (ZIC2 and TGIF1), consistent with the "autosomal dominant with modifier" model. Modifier alleles are classically categorized as phenotypic enhancers or suppressors (Kousi & Katsanis, 2015) . Given that the R533L and P828R variants showed a loss of function, they would be predicted to further diminish a reduction of SHH signaling associated with heterozygosity for ZIC2 or TGIF1, and are likely enhancers of the phenotypic outcome in these patients. Both these variants are also found in the general population as listed by the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org). R533L is rare, but
Cdon -/-mice display modifier-dependent HPE phenotypes. (a1-a3) Cdon -/-mice on a 129S6 genetic background are largely normal, displaying two nostrils and normally partitioned upper lip (a1; arrow); two optic vesicles (a2; arrowheads); and normally partitioned forebrain (a3). We note that a minority of these mice show mild midfacial defects (not shown, see text). (b1) Genetic removal of Boc enhances this phenotype in a dosage sensitive manner, resulting in pronounced midfacial midline hypoplasia, fused upper lip, and single nostril (red arrow). (c1-c3) In utero exposure of 129S6 Cdon -/-mice to alcohol leads to a full spectrum of HPE phenotypes, including in: (c1) single nostril (a mid-severity phenotype; arrow); (c2) unpartitioned forebrain plus cyclopia (the most severe phenotypes; arrow and arrowhead, respectively); and (c3) partitioned forebrain with ventral continuity (a mild phenotype; arrow). (d1) Genetic removal of one copy of the negative Shh pathway regulator Ptch1 rescues HPE phenotypes in alcohol-treated 129S6 Cdon -/-mice. (e1, e2) C57BL/6 Cdon -/-have more severe HPE than 129S6 Cdon -/-mice, and show single nostril (e1; arrow) and unpartitioned forebrain (e2; arrow). (f1, f2) Genetic removal of Boc enhances this phenotype in a dosage sensitive manner, resulting in severely hypoplastic midface and hypotelorism (f1) and cleft lip (f2; arrow). All whole mount embryos are at E14.5 or E15.5. Sections are at E10.5 (a2, c2, e2) and E14.5 (a3, c3) P828R had a minor allele frequency of 0.0017. This is higher than the 1:10,000 live birth frequency of HPE and also consistent with modifier function. One other BOC variant identified in this study (G556E) had never been reported before in any population and displayed a Shh-dependent gain of function. This is opposite what would be expected for causation in HPE. Ninety-seven percent of HPE cases succumb in utero and are not available for DNA sequence analyses.
We speculate that this patient may have survived long enough for such an analysis because the G556E allele acted as a partial phenotypic suppressor of an unidentified insult that inhibited SHH signaling during development of the rostroventral midline. Similar protective effects have been seen in mouse HPE models by removal of one copy of the negative Hh pathway regulator Ptch1 (Geng, Acosta, Lagutin, Gil, & Oliver, 2016; Hong & Krauss, 2013) . Taken together, the combination of: (a) both loss-and gain-of-function properties (enhancer and suppressor, respectively); (b) co-occurrence of BOC variants with bona fide pathogenic variants of HPE genes; and (c) BOC allele frequencies, provided strong evidence that BOC is a modifier gene in HPE, the first to be identified (Hong & Krauss, 2017) . Furthermore, this finding validates the use of mouse models as one foothold into the very difficult problem of identifying silent modifier genes in HPE patients.
| G EN E-E NV I RON M E NT I NTE R AC TI ONS I N H P E
Small molecule inhibitors of Shh signaling, if sufficiently potent, are HPE-inducing teratogens in animals (Chen, 2016; Heyne et al., 2015) .
The first such molecule discovered is the naturally occurring teratogen and SMO antagonist, cyclopamine (Chen, 2016 (Johnson & Rasmussen, 2010; Miller et al., 2010) . It must be emphasized that environmental risk factors need not act as complete teratogens to be involved etiologically in HPE, as they may serve as modifiers of germline mutations which predispose individuals to HPE. This type of scenario could arise either because a given environmental factor is intrinsically insufficient as a teratogen (analogous to silent modifier genes) or because the exposure dosage and/or timing are suboptimal.
Many structural birth defects are likely to arise from a complex combination of genetic and environmental influences (Krauss & Hong, 2016) . Identifying gene-environment interactions in birth defect etiology is difficult, particularly if the interactions occur only between specific subsets of all the genetic and nongenetic risk factors potentially involved. Mouse models are particularly well-suited to address this issue. The first reported example of gene-environment interaction in HPE concerned lowering of cholesterol levels (Lanoue et al., 1997) .
Cholesterol promotes Shh signaling in multiple ways, including covalent adduction of Hh ligands themselves and direct interaction with Smo (Byrne, Luchetti, Rohatgi, & Siebold, 2018; Mann & Beachy, 2004) . 3b-hydroxysterol-D7-reductase catalyzes the final step in cholesterol biosynthesis and is encoded by DHCR7. Autosomal recessive mutations in DHCR7 cause Smith-Lemli-Opitz syndrome (SLOS) (Kelley & Herman, 2001 ). Consistent with the need for sufficient levels of cholesterol for Shh signaling, some individuals with SLOS have HPE (Haas & Muenke, 2010) . Lanoue et al. (1997) showed that when mice genetically deficient for apoliporotein B (which have low cholesterol levels) were exposed in utero to the DHCR7 inhibitor BM15.766, a fraction of the embryos were holoprosencephalic. While this represents an extreme lowering of cholesterol, the study demonstrated that mutations and chemicals affecting a similar process could synergize to produce HPE.
Furthermore, the findings add weight to the recommendation that women who take statin drugs to lower cholesterol should not do so when pregnant (Haas & Muenke, 2010) .
The notion that subthreshold combinations of genetic and chemical inhibition of Shh signaling can produce HPE spectrum phenotypes was specifically probed by Lipinski and colleagues. Vismodegib is a potent, Food and Drug Administration (FDA)-approved SMO inhibitor (Sharpe, Wang, Hannoush, & de Sauvage, 2015) . Single dose (40 mg/ kg), in utero exposure to Vismodegib induced HPE in 80% of C57BL/ 6 mice (Heyne et al., 2015) . Gli2 -/-mice on this background also had HPE, but Gli2 1/-mice did not (Heyne et al., 2016) . However, Gli2
1/-mice were sensitized to Vismodegib relative to wild type mice, displaying increased HPE penetrance and severity in response to doses of 2.5
and 10 mg/kg (Heyne et al., 2016) . SMO is a complex protein, with multiple allosteric sites (Sharpe et al., 2015) . It is targeted by many natural and man-made small molecule antagonists, and many more are likely to be discovered. Some of these are probably of a potency lower than that needed for sufficiency as an HPE-inducing teratogen (Lipinski & Bushman, 2010) . However, individuals with heterozygous mutations in HH pathway genes may be sensitized to such compounds, making them potential modifiers in an "autosomal dominant with modifier" scenario.
Ethanol is a human teratogen, responsible for fetal alcohol spectrum disorders (FASDs) (Mead & Sarkar, 2014) . It has also been implicated in HPE, although epidemiological studies have been inconsistent on this point (Croen et al., 2000; Johnson & Rasmussen, 2010; Miller et al., 2010) . Ethanol is teratogenic to mouse embryos, but this occurs in a strain-specific manner (Aoto, Shikata, Higashiyama, Shiota, & Motoyama, 2008; Downing, Balderrama-Durbin, Broncucia, Gilliam, & Johnson, 2009; Hong & Krauss, 2012) . C57BL/6 mice are sensitive to fetal ethanol, developing FASD-like craniofacial phenotypes; additionally, 20% of the embryos show HPE spectrum defects (Aoto et al., 2008; Sulik, Johnston, & Webb, 1981) . In contrast, 129S6 mice are resistant to ethanol-induced teratogenesis (Downing et al., 2009; Hong & Krauss, 2012) . As 129S6 Cdon -/-mice are a sensitized line to identify genetic HPE modifiers, we tested the possibility that these animals were also sensitized to fetal alcohol-induced HPE. In 129S6 mice, Cdon mutation resulted in mild and infrequent HPE phenotypes and in utero ethanol exposure was without effect, but together they produced the full HPE spectrum with 75% penetrance (Hong & Krauss, 2012) HONG AND KRAUSS | 145 (Figure 2 ). This included alobar HPE with cyclopia, which is not seen in any of the purely genetic HPE models that involve Cdon mutation. In addition, certain phenotypes found in human HPE only infrequently, such as agnathia and ocular coloboma, arose at a similar low penetrance in these embryos. (Hong & Krauss, 2012 . Importantly, HPE associated with fetal ethanol exposure in C57BL/6 mice was exacerbated in mice of this background that were heterozygous for either Shh or Gli2 (Kietzman, Everson, Sulik, & Lipinski, 2014) , indicating that the phenomenon is generalizable.
Mouse models offer a means to understand mechanistic underpinnings of teratogen action and gene-environment interactions. We have pursued such questions in the Cdon mutation plus fetal ethanol model.
Many of ethanol's toxic effects are ascribed to its oxidative metabolism (Cederbaum, 2012) . Ethanol is metabolized by alcohol dehydrogenase (ADH) to acetaldehyde, which is in turn metabolized by aldehyde dehydrogenase to harmless acetate. Acetaldehyde is a teratogen and a source of oxidative stress. Cytochrome P450 2E1 (Cyp2E1) metabolizes ethanol to acetaldehyde as well, and though less important quantitatively than ADH, it produces reactive oxygen species as part of its catalytic action (Cederbaum, 2012) . A potential alternative, nonmetabolism-based, teratogenic mechanism is that ethanol itself has solvent properties and perturbs cellular membranes (Goldstein, 1986; Klemm, 1990) . To address whether oxidative metabolism is required for ethanol's action as an HPE teratogen, we tested whether t-butyl alcohol was teratogenic. t-butyl alcohol is neither a substrate nor an inhibitor of ADH or Cyp2E1; nevertheless, it induced HPE in Cdon -/-mice similarly to ethanol, but at lower doses (Hong & Krauss, 2017) .
Because ethanol may generate oxidative stress through its metabolism as well as via a more general toxicity, we tested whether antioxidant treatment influenced its ability to induce HPE. Strikingly, an antioxidant regimen that completely blocked ethanol-induced production of reactive oxidant species had no effect on its teratogenic effects (Hong & Krauss, 2017) . Together, these results are consistent with the conclusion that ethanol itself is the HPE-inducing teratogen, not consequences of its metabolism or oxidative stress.
This finding has practical consequences. Ethanol is rapidly metabolized, and is undetectable in the blood of female mice less than 24 hr after administration (Hong & Krauss, 2012) . To determine a window of sensitivity, pregnant females were administered ethanol at several different time points during gestation. Ethanol was teratogenic to Cdon -/-mice when given at embryonic day (E) 7.0 and E7.25, but not earlier and not at E7.5 or later (Aoto et al., 2008; Hong & Krauss, 2012; M.H., unpublished results) . This very narrow window (<12 hr) corresponds to the third week of human pregnancy, a time many women do not know they are pregnant.
Because ethanol itself appears to be the culprit, the developmental processes that are its direct targets must occur: (a) during the sensitive time window; and (b) before ethanol is metabolized. Shh signaling from the PCM begins at about E7.75, after almost all the ethanol has been metabolized in mice treated at E7.0. Additionally, the window of sensitivity for HPE induced by the direct Hh pathway inhibitor Vismodegib peaks at E7.5, later than for ethanol (Heyne et al., 2015) . Therefore, Hh signaling is very unlikely to be the direct target of ethanol. We note that this is not inconsistent with a requirement for inhibition of Hh signaling during ethanol-induced HPE (Hong & Krauss, 2013) ing rostroventral midline patterning the failure to reach threshold occurs, the more severe the ensuing HPE phenotype (Cordero et al., 2004; Krauss, 2007; Marcucio et al., 2011) .
| CON CL U SI ONS A N D FU T U RE DI R E CTI ON S
HPE arises from a complex interaction between germline mutations and modifier effects, both genetic and environmental. This has made a full understanding of HPE etiology challenging. We have argued here that the mouse, a genetically tractable system sensitive to teratogens, provides a model to address this challenge. Validation of this point of view is that Boc was initially found to be a silent HPE modifier gene in mice and was subsequently identified to be a modifier gene in human HPE. Similarly, ethanol is a suspect HPE teratogen, and studies with mice argue that this may be so in humans, but genetically predisposed individuals (e.g., those harboring SHH pathway mutations) may be particularly susceptible. Additionally, mice offer opportunities to decipher mechanisms in causation of HPE. Our finding that ethanol itself is the likely HPE teratogen, perhaps acting as a membrane-active agent, suggests that other environmental chemicals with solvent-like properties may have similar teratogenic effects.
Studies with human HPE cohorts and mouse models raise interesting questions that will be most easily addressed in mice, at least initially. One such question concerns the complexity of modifiers in HPE.
Although, the presence of more than one bona fide driver mutation is uncommon in human HPE, it may be that multiple modifying influences -both genetic and environmental, sensitizing and protective-interact to grade the phenotypic response to a mutation. Another question is whether multiple HPE-enhancing modifiers could be sufficient to produce HPE in the absence of a driver mutation. Driver mutations have not been found in most isolated HPE cases. The percentage of cases that do have identified mutations will undoubtedly rise with the application of whole genome sequencing of triads. However, the notion that accumulation of many "smaller" insults might produce HPE is important to consider. As an initial test of this possibility, we assessed whether 129S6 Boc -/-mice were sensitive to ethanol-induced HPE (i.e., a genetic modifier plus an environmental modifier); these mice did not have HPE (Hong & Krauss, 2012) . It may be that a strong driver insult is always necessary or that, in the absence of a bona fide mutation, several enhancing modifiers are required to produce HPE. The mouse will be a good model to explore this question. Finally, mutations in at least 14 genes have been identified in isolated HPE, with none accounting for a very high percentage of total cases. While it is still early days in the identification of modifiers, it can be envisaged that their number is higher. The heterogeneity of human genomes and the environments in which they live, plus the complexity of HPE causation and the wide range of its associated phenotypes, suggests that each case may be different. Although that is a daunting thought, some clear concepts have been established in HPE etiology. A combination of studies with human cohorts and increasingly complex mouse models should continue to improve our understanding of this fascinating and medically important issue.
